Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Integrin αVβ3 is a heterodimeric cell surface receptor composed of αV and β3 subunits. It mediates cell adhesion to the extracellular matrix via RGD motifs, primarily found in vitronectin, fibronectin, fibrinogen, laminin, thrombospondin, vWF, osteopontin and tenascin. It plays a critical role in angiogenesis, bone resorption, and cell signaling, and is implicated in cancer, cardiovascular disorders, and autoimmune diseases. It is a target for antiangiogenic therapies.
αVβ3 antagonists inhibit angiogenesis by blocking the interaction of αVβ3 with ECM proteins and growth factors, leading to reduced endothelial cell proliferation, migration, and survival. Some antagonists, like ProAgio, induce apoptosis by recruiting caspase 8 to the receptor.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Integrin alpha-V beta3 (αVβ3).